137 related articles for article (PubMed ID: 37805291)
1. [Early detection of prostate cancer: Towards a new paradigm?].
Peyrottes A; Rouprêt M; Fiard G; Fromont G; Barret E; Brureau L; Créhange G; Gauthé M; Baboudjian M; Renard-Penna R; Roubaud G; Rozet F; Sargos P; Ruffion A; Mathieu R; Beauval JB; De La Taille A; Ploussard G; Dariane C
Prog Urol; 2023 Dec; 33(15-16):956-965. PubMed ID: 37805291
[TBL] [Abstract][Full Text] [Related]
2. How MRI is changing prostate cancer management: a focus on early detection and active surveillance: Comment l'IRM est en train de révolutionner la prise en charge du cancer de la prostate : focus sur la détection précoce et la surveillance active.
Fiard G; Giganti F
Prog Urol; 2022 Jun; 32(6S1):6S19-6S25. PubMed ID: 36719642
[TBL] [Abstract][Full Text] [Related]
3. Structured Population-based Prostate-specific Antigen Screening for Prostate Cancer: The European Association of Urology Position in 2019.
Gandaglia G; Albers P; Abrahamsson PA; Briganti A; Catto JWF; Chapple CR; Montorsi F; Mottet N; Roobol MJ; Sønksen J; Wirth M; van Poppel H
Eur Urol; 2019 Aug; 76(2):142-150. PubMed ID: 31092338
[TBL] [Abstract][Full Text] [Related]
4. Multiparametric MRI in detection and staging of prostate cancer.
Boesen L
Dan Med J; 2017 Feb; 64(2):. PubMed ID: 28157066
[TBL] [Abstract][Full Text] [Related]
5. Prostate cancer screening using a combination of risk-prediction, MRI, and targeted prostate biopsies (STHLM3-MRI): a prospective, population-based, randomised, open-label, non-inferiority trial.
Nordström T; Discacciati A; Bergman M; Clements M; Aly M; Annerstedt M; Glaessgen A; Carlsson S; Jäderling F; Eklund M; Grönberg H;
Lancet Oncol; 2021 Sep; 22(9):1240-1249. PubMed ID: 34391509
[TBL] [Abstract][Full Text] [Related]
6. Prebiopsy Multiparametric Magnetic Resonance Imaging for Prostate Cancer Diagnosis in Biopsy-naive Men with Suspected Prostate Cancer Based on Elevated Prostate-specific Antigen Values: Results from a Randomized Prospective Blinded Controlled Trial.
Tonttila PP; Lantto J; Pääkkö E; Piippo U; Kauppila S; Lammentausta E; Ohtonen P; Vaarala MH
Eur Urol; 2016 Mar; 69(3):419-25. PubMed ID: 26033153
[TBL] [Abstract][Full Text] [Related]
7. A comparison of magnetic resonance imaging techniques used to secure biopsies in prostate cancer patients.
van Luijtelaar A; Bomers J; Fütterer J
Expert Rev Anticancer Ther; 2019 Aug; 19(8):705-716. PubMed ID: 31277551
[No Abstract] [Full Text] [Related]
8. EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent.
Mottet N; Bellmunt J; Bolla M; Briers E; Cumberbatch MG; De Santis M; Fossati N; Gross T; Henry AM; Joniau S; Lam TB; Mason MD; Matveev VB; Moldovan PC; van den Bergh RCN; Van den Broeck T; van der Poel HG; van der Kwast TH; Rouvière O; Schoots IG; Wiegel T; Cornford P
Eur Urol; 2017 Apr; 71(4):618-629. PubMed ID: 27568654
[TBL] [Abstract][Full Text] [Related]
9. Multiparametric magnetic resonance imaging (MRI) and subsequent MRI/ultrasonography fusion-guided biopsy increase the detection of anteriorly located prostate cancers.
Volkin D; Turkbey B; Hoang AN; Rais-Bahrami S; Yerram N; Walton-Diaz A; Nix JW; Wood BJ; Choyke PL; Pinto PA
BJU Int; 2014 Dec; 114(6b):E43-E49. PubMed ID: 24712649
[TBL] [Abstract][Full Text] [Related]
10. Combined Clinical Parameters and Multiparametric Magnetic Resonance Imaging for Advanced Risk Modeling of Prostate Cancer-Patient-tailored Risk Stratification Can Reduce Unnecessary Biopsies.
Radtke JP; Wiesenfarth M; Kesch C; Freitag MT; Alt CD; Celik K; Distler F; Roth W; Wieczorek K; Stock C; Duensing S; Roethke MC; Teber D; Schlemmer HP; Hohenfellner M; Bonekamp D; Hadaschik BA
Eur Urol; 2017 Dec; 72(6):888-896. PubMed ID: 28400169
[TBL] [Abstract][Full Text] [Related]
11. A European Model for an Organised Risk-stratified Early Detection Programme for Prostate Cancer.
Van Poppel H; Hogenhout R; Albers P; van den Bergh RCN; Barentsz JO; Roobol MJ
Eur Urol Oncol; 2021 Oct; 4(5):731-739. PubMed ID: 34364829
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of magnetic resonance imaging and targeted fusion biopsy for early detection of prostate cancer.
Barnett CL; Davenport MS; Montgomery JS; Wei JT; Montie JE; Denton BT
BJU Int; 2018 Jul; 122(1):50-58. PubMed ID: 29388388
[TBL] [Abstract][Full Text] [Related]
13. Implementation of multiparametric magnetic resonance imaging technology for evaluation of patients with suspicion for prostate cancer in the clinical practice setting.
Shah PH; Patel VR; Moreira DM; George AK; Alom M; Kozel Z; Joshi V; Ben-Levi E; Villani R; Yaskiv O; Kavoussi LR; Vira M; Olsson CO; Rastinehad AR
BJU Int; 2019 Feb; 123(2):239-245. PubMed ID: 30113138
[TBL] [Abstract][Full Text] [Related]
14. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
15. Impact of prostate-specific antigen screening on tumor size in patients with prostate cancer in a super-aging district in Kyoto, Japan.
Matsugasumi T; Okihara K; Tsujimoto M; Sato O; Imura T; Yamada Y; Fujihara A; Shiraishi T; Hongo F; Ukimura O
Int J Clin Oncol; 2021 Dec; 26(12):2303-2309. PubMed ID: 34537890
[TBL] [Abstract][Full Text] [Related]
16. [Prostate cancer screening-current overview].
De Vrieze M; Hübner A; Al-Monajjed R; Albers P; Radtke JP; Schimmöller L; Boschheidgen M
Radiologie (Heidelb); 2024 May; ():. PubMed ID: 38743100
[TBL] [Abstract][Full Text] [Related]
17. Prostate-specific Antigen Testing as Part of a Risk-Adapted Early Detection Strategy for Prostate Cancer: European Association of Urology Position and Recommendations for 2021.
Van Poppel H; Roobol MJ; Chapple CR; Catto JWF; N'Dow J; Sønksen J; Stenzl A; Wirth M
Eur Urol; 2021 Dec; 80(6):703-711. PubMed ID: 34407909
[TBL] [Abstract][Full Text] [Related]
18. Prospective study of diagnostic accuracy comparing prostate cancer detection by transrectal ultrasound-guided biopsy versus magnetic resonance (MR) imaging with subsequent MR-guided biopsy in men without previous prostate biopsies.
Pokorny MR; de Rooij M; Duncan E; Schröder FH; Parkinson R; Barentsz JO; Thompson LC
Eur Urol; 2014 Jul; 66(1):22-9. PubMed ID: 24666839
[TBL] [Abstract][Full Text] [Related]
19. Histological inflammation and risk of subsequent prostate cancer among men with initially elevated serum prostate-specific antigen (PSA) concentration in the Finnish prostate cancer screening trial.
Yli-Hemminki TH; Laurila M; Auvinen A; Määttänen L; Huhtala H; Tammela TL; Kujala PM
BJU Int; 2013 Oct; 112(6):735-41. PubMed ID: 23746332
[TBL] [Abstract][Full Text] [Related]
20. Prostate-specific antigen-based early detection of prostate cancer--validation of screening without rectal examination.
Schröder FH; Roobol-Bouts M; Vis AN; van der Kwast T; Kranse R
Urology; 2001 Jan; 57(1):83-90. PubMed ID: 11164149
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
